Exchange: NASDAQ·Updated 07:30 PM EDT

RGEN News

News
all
press releases
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
Zacks
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Zacks
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
Zacks
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
Zacks
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Zacks
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
Zacks
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
Zacks
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
Zacks

Advertisement|Remove ads.